Immunotherapy for Non-Small Cell Lung Cancer: A Comprehensive Review

Lung cancer remains the leading cause of cancer-related mortality worldwide, with NSCLC accounting for over 85% of cases. Conventional chemotherapy and radiotherapy yield modest benefits in survival. The advent of immunotherapies, particularly immune checkpoint inhibitors (ICIs), has drastically shifted the treatment paradigm by harnessing the patient’s immune system to target tumor cells^[1][2].

Mechanism of Action

Immune checkpoint pathways—PD-1/PD-L1 and CTLA-4—act as physiological brakes on immune responses. Tumor cells upregulate PD-L1, binding to PD-1 on T-cells and inactivating them. ICIs—monoclonal antibodies like nivolumab, pembrolizumab (anti-PD-1), atezolizumab, durvalumab (anti-PD-L1), and ipilimumab (anti-CTLA-4)—block these interactions, restoring anti-tumor immunity^[3][1][2].

Approved Agents and Indications

·        Pembrolizumab, Nivolumab (PD-1 inhibitors): Used as first- and subsequent-line therapy for advanced NSCLC, with pembrolizumab approved for PD-L1 ≥1%; nivolumab regardless of biomarker status.

·        Atezolizumab, Durvalumab (PD-L1 inhibitors): Atezolizumab is approved in various lines; durvalumab as adjuvant after chemoradiation in unresectable stage III NSCLC.

·        Ipilimumab (CTLA-4 inhibitor): Used in combination with anti–PD-1/PD-L1 drugs for selected advanced cases^[3][1][2].

Landmark Trials and Patient Outcomes

·        For advanced/metastatic (stage IV) NSCLC, studies repeatedly show that ICIs improve overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone. Combination regimens of chemo-immunotherapy further improve outcomes for many patients^[1][2][4].

·        First-line monotherapy is typically offered to patients with high PD-L1 expression (≥50%), while combination approaches are used for others.

·        Response rates: Approximately 15–25% of unselected patients respond to single-agent immunotherapy, but rates are higher in patients with high PD-L1 or high tumor mutation burden^[3][5].

Early-Stage and Perioperative Use

·        Recent years have seen the extension of ICIs into earlier stages, including neoadjuvant (pre-surgery) and adjuvant (post-surgery) settings. Trials like IMpower010 (atezolizumab), KEYNOTE-091 (pembrolizumab), and CheckMate-816 (nivolumab/chemotherapy) have demonstrated event-free and disease-free survival benefits^[6][7][1].

·        ICIs are now approved as adjuvant/neoadjuvant therapy for resectable stage II–IIIA NSCLC, shifting the standard of care^[6][7].

Graph: Timeline of Immunotherapy Approvals and Key Trials in NSCLC

[image:1]

Biomarkers and Patient Selection

·        PD-L1 expression: Most robust predictor for ICI benefit; however, responses can occur in PD-L1–negative tumors.

·        Tumor mutation burden (TMB): Emerging as a potential biomarker, but its standardized use is limited.

·        Oncogenic drivers: Patients with EGFR/ALK mutations benefit less from immunotherapy and generally receive targeted tyrosine kinase inhibitors as first-line treatment^[5].

Table 1: Summary of Key ICIs Used in NSCLC

Kaplan-Meier Curves: Immunotherapy vs. Chemotherapy for Advanced NSCLC

·        OS at 2 years: ~35–40% (ICI) vs. ~20% (chemotherapy).

·        Durable responses (lasting ≥5 years) occur in a minority of patients, representing a significant improvement over historical controls^[2][4][8].

[image:2]

Safety and Adverse Events

·        Immune-related adverse events (irAEs): Most are mild to moderate but can affect any organ system (skin, lung, gut, endocrine glands).

·        Severe irAEs are less common than severe chemotherapy toxicities but require vigilant monitoring and may necessitate immunosuppression^[3][1][2].

·        The risk/benefit ratio remains favorable for most eligible patients.

Table 2: Common Immune-Related Adverse Events with ICIs

Combination and Future Strategies

·        Combining ICIs with chemotherapy, antiangiogenic agents, or other immunomodulators is under active investigation^[6][1].

·        Novel cellular therapies (CAR-T, TCR-T), bispecific antibodies, and tumor vaccines are being studied, particularly for ICI-refractory disease^[9].

Limitations and Challenges

·        A significant proportion of patients (50–80%) do not respond to ICIs and further work is needed to improve patient selection^[5].

·        Immune resistance, both primary and acquired, and biomarker heterogeneity remain clinical barriers.

·        Adjuvant/neoadjuvant settings present new questions about optimal duration, timing, and long-term safety^[6][7].

Immunotherapy, especially immune checkpoint inhibition, has revolutionized the management of NSCLC across all stages. Ongoing research will refine patient selection, discover novel targets, and optimize combination regimens, promising continued improvements in survival and quality of life for patients with NSCLC.

Acknowledgements

This comprehensive review was prepared for academic and educational reference. No conflicts of interest declared.

1.      Capella, MP, et al. "A Review of Immunotherapy in Non-Small-Cell Lung Cancer." Current Oncology, 2024.

2.      Stanley, R., et al. "Immunotherapy through the Lens of Non-Small Cell Lung Cancer." Cancers, 2023.

3.      Phillips, WJ. "Immunotherapy for Early-Stage Non–Small Cell Lung Cancer." Journal of Thoracic Oncology, 2025.

4.      Lim, SM, et al. "Immunotherapy for Non-small Cell Lung Cancer." Immune Network, 2020.

5.      Sun Min Lim, et al. "Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives." Immune Network, 2020.

6.      Front Pharmacol. "Current status of immunotherapy for non-small cell lung cancer." 2022.

7.      Perlmutter Cancer Center. "Immunotherapy in non-small cell lung cancer: Past, present, and future directions." Frontiers in Oncology, 2022.